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Abstract
Background: Developing the right drugs for the right patients has become a mantra of drug development. In
practice, it is very difficult to identify subsets of patients who will respond to a drug under evaluation. Most of the
time, no single diagnostic will be available, and more complex decision rules will be required to define a sensitive
population, using, for instance, mRNA expression, protein expression or DNA copy number. Moreover, diagnostic
development will often begin with in-vitro cell-line data and a high-dimensional exploratory platform, only later to
be transferred to a diagnostic assay for use with patient samples. In this manuscript, we present a novel approach
to developing robust genomic predictors that are not only capable of generalizing from in-vitro to patient, but are
also amenable to clinically validated assays such as qRT-PCR.
Methods: Using our approach, we constructed a predictor of sensitivity to dacetuzumab, an investigational drug
for CD40-expressing malignancies such as lymphoma using genomic measurements of cell lines treated with
dacetuzumab. Additionally, we evaluated several state-of-the-art prediction methods by independently pairing the
feature selection and classification components of the predictor. In this way, we constructed several predictors that
we validated on an independent DLBCL patient dataset. Similar analyses were performed on genomic
measurements of breast cancer cell lines and patients to construct a predictor of estrogen receptor (ER) status.
Results: The best dacetuzumab sensitivity predictors involved ten or fewer genes and accurately classified
lymphoma patients by their survival and known prognostic subtypes. The best ER status classifiers involved one or
two genes and led to accurate ER status predictions more than 85% of the time. The novel method we proposed
performed as well or better than other methods evaluated.
Conclusions: We demonstrated the feasibility of combining feature selection techniques with classification
methods to develop assays using cell line genomic measurements that performed well in patient data. In both
case studies, we constructed parsimonious models that generalized well from cell lines to patients.
Background
Targeted therapies and individualized medicine have
become buzz-words in drug development [1]. However,
in practice it is extremely difficult to identify molecular
subpopulations expected to respond to an investigational
drug. Trastuzamab, for Her2-positive breast cancer
patients [2], and imatinib, for chronic myeloid leukemia
(CML) driven by 9/22 translocation also known as Phi-
ladelphia chromosome [3], represent rare success stories
for personalized treatment. However, the targeted popu-
lation for these drugs was defined pre-clinically based
on overwhelming scientific evidence. Even for the case
o ft r a s t u z a m a b ,w h e r eas i n g l ed i a g n o s t i cm a r k e ri s
known, the most appropriate assay is still unclear, with
a combination of two assays defining the current clinical
practice.
In most cases, however, a single diagnostic marker is
not available, and more complex decision rules will be
required to define a sensitive population based upon, for
instance, mRNA expression, protein expression or DNA
copy number. This was recognized by the FDA Critical
Path Initiative [1] which calls for development of new
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that can rapidly analyze the expression of thousands of
genes, may make it possible to identify sets of biomarkers
that are more predictive of clinical risks or benefits than
single markers for a given condition. However, develop-
ment of assays to identify likely responders to a drug
based on gene expression measurements has some
inherent difficulties. First, development of such assays
often need to be performed on cell lines rather than
clinical samples, which in many cases are not available
until later in the clinical development cycle. Second,
such assays must only involve a small number of genes.
High dimensional biomarkers or signatures,b i o m a r k e r s
that depend on the expression levels of a large number
of genes, are generally not robust to inherent assay
variability. Furthermore, classifiers involving small num-
bers of genes are conducive to PCR-based assays; even
though development of the classifier may occur on a
microarray, the final diagnostic assay is likely to be
PCR-based. Patients routinely undergo a tissue biopsy
for diagnosis and the biopsy is subsequently Formalin
Fixed and Paraffin Embedded (FFPE). FFPE tissue is
renowned for having poor quality RNA due to extensive
degradation as a result of paraffin embedding as well as
extensive cross-links from formalin fixation which can
also affect the quality of RNA extracted. qRT-PCR
assays have been successfully implemented in clinical
practice from fixed tissue for multi-gene assays, but
such PCR-based assays can only feasibly involve 30 or
fewer genes.
In addressing the development problems described
above, this manuscript deals with two statistical issues
inherent to the problem of developing a robust diagnos-
tic assay: feature selection and model fitting. A great deal
of research has gone into statistical techniques for the
selection of lower-dimensional subsets of variables for
prediction, particularly for cases where the number of
classifiers p is far greater than the number of samples
N, a phenomenon that is characteristic of microarray
data; many oncologic indications only have a limited
number of the cell lines at a time (50 - 100), yet the
expressions of tens of thousands of genes are measured
for each cell line. One prominent example of such a
technique is the Lasso [4], which involves finding coeffi-
cients under the standard multivariate linear regression
model that maximize the log-likelihood subject to a
constraint on the L1-norm of the coefficients, namely
the sum of the absolute values of the coefficients. The
effect of the L1-norm constraint is that many of the
coefficients will be set to exactly zero, thus resulting in
feature selection; we describe this technique in more
detail in the Methods section. Another example is what
we call Self-Normalizing Stepwise Selection (SNSS), a
forward stepwise procedure that adds variables to a
simple signed average according to their strength of
association with the outcome.
Our aim is to explore combinations of feature selec-
tion methods with various alternate model fitting tech-
niques in constructing assays with high responder
versus non-responder classification accuracy. We apply
a feature selection method such as Lasso or SNSS to
cell line data to find the subset of genes that best pre-
dict a cell line’s disease subtype or sensitivity to a drug,
and then employ alternate classification techniques,
such as K-Nearest Neighbors (KNN) [5] or Random
Forests [6], to develop classifiers that we will compare
in terms of responder versus non-responder classifica-
tion accuracy.
We apply this approach to two case studies. In the
first, we use cell line gene expression and sensitivity to
dacetuzumab (SGN-40) [7,8], a drug targeting malignant
B-cells, to construct a predictive model of diffuse large
B-cell lymphoma (DLBCL) patient sensitivity to the
same drug. In the second, we use gene expression data
from breast cancer cell lines to develop classifiers of
estrogen receptor (ER) status for application in breast
cancer patients. The molecular classification of breast
cancer is of high importance due to patient subtype-spe-
cific prognoses and the subtype-specificity of potential
drug targets [9,10]. While the IHC assay for ER status is
a widely accepted standard, we used expression-based
ER prediction as another case study for comparing the
performance of classifiers.
For the rest of the paper, we will assume that the
genomic data represents genome-wide mRNA expres-
sion measurements, and we will use the terms biomar-
ker, gene signature,a n dclassifier interchangeably. The
methods we develop are not specific to any technology
or experimental setting.
The Data and the Two Case Studies
As the first case study, we apply the proposed metho-
dology to predict, based on the cell line data, the sensi-
tivity of the diffuse large B-cell lymphoma (DLBCL)
patients to dacetuzumab, a drug for DLBCL developed
jointly by Seattle Genetics, Inc. and Genentech, Inc.
Non-Hodgkin’s lymphoma (NHL) consists of a diverse
group of lymphoid neoplasms that, in the United States,
rank sixth in estimated incidence of new cancer cases
and ninth and sixth in estimated cancer mortality
among men and women, respectively. It is estimated
that in 2009, NHL accounted for 3% and 4% of cancer
deaths of men and women, respectively, in the United
States [11]. Diffuse large B-cell lymphoma (DLBCL), the
most common histologic subtype of Non-Hodgkin’s
lymphoma (NHL), accounts for approximately 30 per-
cent of NHL cases. DLBCL arises from a mature B-cell,
the majority of which express a CD20+ cell-surface
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fied in subsets of DLBCL. The most frequently dysregu-
lated genes include BCL-6, BCL-2, and cMYC [12].
Dacetuzumab targets the B-cell CD40 pathway, which
acts as a trigger for the transformation of germinal cen-
ter B-cells into activated B-cells. Pre-clinical evidence
suggests that dacetuzumab is most active in DLBCL cell
lines with inactive CD40 pathways [8]. In these cell
lines, dacetuzumab may stimulate the pathway, initiating
cell signaling cascades that interfere with the function-
ing of the tumor cell. On the other hand, cell lines with
activated CD40 pathways may be less sensitive to further
signaling by dacetuzumab. Previously, Alizadeh et al
divided DLBCL samples into germinal center B-cell like
(GCB) and activated B-cell like (ABC) subtypes using
gene expression profiling [13]. The GCB and ABC sub-
types are strongly correlated with inactive or active
CD40 pathways in cell lines. In addition, the GCB sub-
type has been reported to be associated with better
overall and progression-free survival. Hence, there is a
strong prior scientific case that groups of patients pre-
dicted to respond to dacetuzumab therapy should over-
lap with the GCB subtype malignancy, and hence the
signature for Dacetuzumab sensitivity should be
enriched for the patients of the GCB subtype and with
better survival.
T h ec e l ll i n ed a t ac o n s i s to fs e n s i t i v i t i e st od a c e t u z u -
mab and approximately 50 thousand Affy U133Plus2.0
platform probe set measurements of the gene expres-
sions for 31 cell lines. We have three replicates of the
probe set measurements for each of the cell lines. Each
cell line was treated with up to 1 μg per mL of dacetu-
zumab; a cell line was labeled as dacetuzumab sensitive
if the IC25, the dosage required to kill 25% of the cells,
was less than 0.4 μg per mL, as dacetuzumab intermedi-
ate or semi-sensitive if the IC25 was greater than 0.4 μg
per mL but less than 1 μg per mL, and as dacetuzumab
resistant if 1 μg per mL was insufficient to kill 25% of
the cells (see Figure 1). Meanwhile, the previously pub-
lished observational patient data include microarray
measurements for 20 thousand probe sets on a U133A
platform, DLBCL subtypes (ABC, GCB, or unclassifi-
able), and survival data (number of months until
their follow-up and status, namely dead or alive, at time
of follow-up) for 221 patients (GEO Accession ID
GSE4475) [14].
In the second case study, we examine the performance
of our methodologies in developing classifiers for estro-
gen receptor (ER) positivity. While the IHC-based assay
for ER positivity is well established, we use ER status
prediction as a base case for the classifiers.
To construct ER status classifiers, we use cell line
genomic data consisting of measurements of approxi-
mately 22 thousand probe sets on an Affy U133A
platform for 65 cell lines (ArrayExpress Accession ID
E-TABM-157) [15]. However, for eighteen of these cell
lines, the ER status is missing ;w eo n l yu s ed a t af o rt h e
remaining 47 cell lines to construct our classifiers. The
ER status assigned to each of these cell lines was based
on previously published literature using copy number,
gene and protein expression data.
We test these classifiers on a data set containing Affy
U133A measurements for 118 breast cancer patients
(ArrayExpress Accession ID E-TABM-158) [10]. The ER
status for each patient is known based on the clinical
assay. Both cell lines and tumor breast cancer datasets
referenced above are described in the Cancer Cell com-
panion manuscripts [10,15]. These papers present a
comprehensive review of the variety of genomic altera-
tions arising in breast tumors and demonstrate the con-
cordance of these alterations between primary tumors
and cell lines as well as examine the relevance of the
observed changes to clinical phenotypes.
Methods
Figure 2 is a schematic of the overall procedure. Using
the cell line data, we perform feature selection followed
by model fitting, thus forming classifiers for dacetuzu-
mab sensitivity or ER status. These classifiers are then
applied to patient data, allowing assessment of the per-
formance of each method.
Feature Selection
In our feature selection procedures, we search for a
small subset of genes with predictive or prognostic
power out of the genome-wide candidate pool. For this,
we consider three techniques:
￿ Lasso [4]. Here, we adopt a general linear model
of phenotype with respect to gene expressions:
gY X j
j
p
j () =
= ∑
1
(1)
Y denotes a numeric coding of the phenotype and Xj
the measurement for probe set j. For the dacetuzu-
mab sensitivity example, Y = 0 denotes sensitivity,
Y = 1 semi-sensitivity, and Y = 2 resistance, whereas
for the ER status example, Y = 1 denotes ER positiv-
ity and Y = 0 denotes ER negativity. g,m e a n w h i l e ,i s
a link function, whose form depends on the charac-
teristics of Y . For ordered or quantitative pheno-
types such as dacetuzumab sensitivity, g(Y)i st h e
expected value of Y conditioned on the values of Xj.
For ER status, a categorical phenotype, g(Y)i st h e
logit of the probability of being ER positive, given
the values of Xj.
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tion between the probe set measurements and the
phenotype, which we must estimate from the data.
Intuitively, bj will be large in magnitude if the mea-
surements in probe set j are strongly associated with
the phenotype and will be zero if there is no such
association.
The Lasso is a technique to estimate these bj given
the data. Note that estimating bj goes hand in hand
with feature selection; those genes for which we set
t h ee s t i m a t eo fbj equal to zero are the ones we do
not include in our set of selected features. In the
Lasso, the estimates of the bj, ˆ  j ,a r et h o s et h a t
maximize the log-likelihood subject to a penalty on
t h es u mo ft h ea b s o l u t ev a l u e so ft h ebj estimates
(an L1-norm penalty); the geometry of this constraint
causes the estimates of many of the bj to be set
equal to exactly zero. We specify the severity of this
penalty through a shrinkage parameter l;t h en u m -
ber of nonzero bj estimates is related to l. We select
l through the cell line data; we describe how to
select the value of l in the Parameter Optimization
subsection that appears later in this section.
￿ SNSS. This technique involves a similar setup as
the Lasso: we adopt the same general linear model
( 1 )a n dg i v e nt h ed a t a ,w ee s t i m a t et h ebj coeffi-
cients. But unlike the Lasso, which performs feature
selection through penalization (soft thresholding),
SNSS does it through hard thresholding. SNSS is a
forward stepwise procedure subject to a hard thresh-
old on the number of genes; at each step, we add
the gene with the strongest predictive signal to the
set of selected features. We have the option of add-
ing a single gene with a substantial predictive signal
at each step, or a pair of genes: a gene with predic-
tive signal and its most negatively correlated gene.
Also, in SNSS, in order to avoid overfitting to the
cell line data, we set bj equal to 1 or -1 according to
the direction of association between the phenotype
and the probe set measurement.
￿ Regularized Discriminant Analysis (RDA) [16].
Whereas in the Lasso and SNSS, we perform feature
selection based on the general linear model (1), in
RDA, we select our genes based on classifications
according to the distributions of the sub-populations
as defined through the various phenotypes.
Figure 1 Plots of sensitivities to dacetuzumab of each of the 31 cell lines used in this case study. A plot of the dacetuzumab IC25
(in μg/mL) of each of the 31 cell lines used in the dacetuzumab sensitivity case study, taken from results originally reported by Burington et al
(Burington, B., Yue, P., Shi, X., et al: CD40 Pathway Activation Status Predicts the Anti-Tumor Activity of CD40 Therapy in Diffuse Large B-Cell
Lymphoma, submitted). The IC25 is defined as the dosage required to kill 25% of the cells. A maximum dosage of 1 μg/mL was administered to
each of the cell lines. We define a cell line as sensitive if the IC25 is below 0.4 μg/mL, semi-sensitive if the IC25 is between 0.4 and 1 μg/mL, and
resistant if the maximum dosage was insufficient to kill 25% of the cells.
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gene expressions, and we subsequently apply this classifier to patient genomic data to classify these patients according to phenotype.
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[17] suitable for high-dimensional cases. We define
sub-populations according to the different pheno-
types; for instance, dacetuzumab sensitive samples
comprise one sub-population, dacetuzumab semi-
sensitive ones form another, and dacetuzumab resis-
tant ones a third. For the purposes of this particular
technique, we assume that for each sub-population,
the distribution of the probe set measurements is
approximately multivariate Normal; the means (cen-
troids) vary across sub-populations, but the variances
do not. Given the data, we estimate the distributions
that characterize each sub-population.
In order to perform feature selection here, we look
only for probe sets whose mean expression differ sub-
stantially between sub-populations by imposing a
soft-thresholding step similar to the one used in the
Lasso. Like in the Lasso, we control the degree of this
soft-thresholding through a shrinkage parameter Δ.
This procedure, however, also needs a shrinkage
parameter for the sub-population distribution var-
iances; often, in high-dimensional cases, the number
of dimensions exceeds the number of samples, which
would result in computational problems. To remedy
t h i s ,w eu s eas h r u n k e ne s t i m a t eo ft h ev a r i a n c e s ;w e
control the degree of this shrinkage through the cov-
ariance matrix parameter a. We also need to find
appropriate values of a and Δ given the data; we
describe this in further detail in the Parameter Opti-
mization subsection that appears later in this section.
Model Fitting
After we use the Lasso, SNSS, or RDA for feature selec-
tion, we use a classification technique to derive a classi-
fication rule based on the selected genes. Here, we
consider three options:
￿ Use the model for feature selection for classifica-
tion also. Suppose we have the probe set measure-
ments XX X p 12
∗∗ ∗ … ,, for a new sample. If we had
used the Lasso and SNSS for feature selection, then
given our estimates of bj, ˆ  j, we use the quantity
ˆ  jj
j
p
X
∗
= ∑
1
(2)
to predict the new sample’s phenotype.
For ordered phenotypes such as dacetuzumab sensitiv-
ity, we assign the new sample to the phenotype whose
numeric coding Y is closest to the quantity (2). In the
context of the dacetuzumab sensitivity example, since
Y = 0 denotes sensitivity, Y = 1 semi-sensitivity, and
Y = 2 resistance, high values for (2) should correspond
to dacetuzumab resistance, low values to sensitivity,
and intermediate values to semi-sensitivity. Thus, we
would classify this new sample as dacetuzumab sensi-
tive if (2) is below a prescribed threshold, resistant if
this quantity is above another higher threshold, and
semi-sensitive otherwise.
For categorical phenotypes such as ER status, (2)
becomes an estimate of the logit probability that the
new sample is of the phenotype corresponding to
Y = 1, namely an estimate of the logit probability
that the new sample is ER positive. Therefore, if (2)
is above a certain threshold, we classify the new
sample as ER positive; otherwise, we classify the new
sample as ER negative.
Meanwhile, for RDA, recall that in the feature selec-
tion step, we defined sub-populations according to
the phenotypes and then estimated the distribution
of the probe set measurements for each sub-popula-
tion. Given the probe set measurements for the
new sample, we determine the probability that
XX X p 12
∗∗ ∗ … ,, , came from each sub-population’s
multivariate normal distribution. The sub-popula-
tion, and consequently the phenotype, we assign to
the new sample is the one corresponding to the
highest such probability.
￿ Construct a K-Nearest Neighbors (KNN) [5]
classifier based on only the selected genes.
Here, we classify a new sample according to the phe-
notype of the cell line whose expressions of the
selected genes are closest in Euclidean distance.
￿ Construct a Random Forests [6] classifier based
on only the relevant genes. We construct an ensem-
ble of B classification trees [5] using subsets of the
genes we selected from the feature selection step. We
apply each of these B trees to the probe measurements
of a new sample, producing B classifications (one for
each tree). The final classification is decided according
to a majority vote among these B classifications.
Parameter Optimization
Part of the classifier construction procedure involves the
selection of appropriate regularization parameter values.
All three feature selection techniques we consider; the
Lasso, SNSS, and RDA; involve regularization para-
meters that we must select. Lasso requires a choice for
the shrinkage parameter l, SNSS requires a choice of
the number of variables to include in the classifier, and
RDA requires choices for two shrinkage parameters: a
for the covariance matrices of the sub-population distri-
butions, and Δ for the soft-thresholding.
The choice of parameter values is a key determinant
of prediction performance. If models are underfit either
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cient optimization, prediction performance can fall short
of the best achievable. Alternatively, models that are
overfit, which include too many genes without appropri-
ate constraints on coefficient fitting will tend to inter-
pret the data points in the training sample, essentially
fitting to noise, so that prediction performance will be
poor on validation samples. The Lasso is an example of
a method in which one parameter constrains both the
number of genes and the degree coefficient fitting. SNSS
in contrast cannot overfit coefficients, which are set to
-1 and 1, so only the number of genes can be con-
strained. Nevertheless, both models will interpolate the
data when fitted with lax constraints.
We find appropriate values for the parameters based
on the cell line data; specifically, we find the ones that
result in the lowest generalization error. We generate a
list of candidate parameter values and estimate the
expected generalization error resulting from each one;
finally, we select the one parameter value that results in
the lowest estimated generalization error. We obtain
estimates of the generalization errors through out-of-
bag (OOB) [18] errors by applying the following proce-
dure to the cell line data:
for each candidate parameter value do
for b = 1, 2, ..., B do
training samples ¬ cell lines sampled N times
with replacement
out-of-bag samples ¬ cell lines not included
among training samples
selected variables ¬ variables selected via applica-
tion of feature selection technique (e. g. Lasso, SNSS) to
training samples
classifications ¬ predicted phenotypes of out-of-
bag samples given selected variables
end for
final classifications ¬ final classification of each cell
line by majority vote over B iterations of above
procedure
optimal parameter value ¬ parameter value corre-
sponding to lowest out-of-bag error
end for
We also illustrate this algorithm in Figure 3.
We then develop the final classifier by applying the
Lasso, SNSS, or RDA, in conjunction with one of the
model fitting techniques, to the full cell line dataset
using the selected parameter value.
For the remainder of this paper, we notate classifiers
as (feature selection technique used)/(classification tech-
n i q u eu s e d ) .F o re x a m p l e ,ac l a s s i f i e rw h e r ew eu s et h e
Lasso for feature selection and KNN for classification
will be Lasso/KNN, whereas one where we use RDA for
feature selection and the RDA model for classification is
RDA/RDA.
Results
First Case Study: Dacetuzumab Sensitivity Classification
We apply each feature selection techniques in combina-
tion with a classifier to the cell line data to construct
dacetuzumab sensitivity classifiers, which we then apply
to independent patient data, classifying each patient as
dacetuzumab sensitive, semi-sensitive, or resistant. We
assess the performance of the classifiers against the
patients’ clinical outcomes.
Ideally, the predictions would be compared to patient
responses to dacetuzumab. However, due to the pre-
clinical initiation of the companion diagnostics develop-
ment, no clinical data on dacetuzumab sensitivity were
available for this analysis. As we have discussed in the
Background section, the patients sensitive to dacetuzu-
mab are expected to be predominantly of GCB subtype
and have better survival rates, whereas the resistant
patients are expected to be predominantly of ABC sub-
type and have poorer survival rates. Thus in this case
study, the relative performance of classifiers may be
assessed using prognostic information.
Recall that we consider three different feature selec-
tion techniques, the Lasso, SNSS, and RDA, in combina-
tion with three different classification approaches: (1)
using the same model for classification as for feature
selection, (2) using the selected features in a KNN clas-
sifier, or (3) using the selected features in a Random
Forests classifier. Thus, we have constructed a total of
nine classifiers. In order to assess the performance of
each classifier, we compare prediction of sensitive, semi-
sensitive, and resistant class membership to survival and
to GCB/ABC/unknown subtypes.
Prior to our analysis, we perform some necessary pre-
processing steps for the purposes of quality control.
First, we filter out probe sets with high relative within-
to-between biological replicate variability [19], which
can be shown to be related to correlation between
paired replicates. High variability within replicates on a
biological sample matters only when that variability is
large relative to the variability across biological samples,
and if this ratio is too high, then the Pearson and Spear-
man correlation between replicate pairs will be low,
indicating that the biological samples cannot be consis-
tently ranked. Without consistent rankings from the
predictors, good classification is not possible. We also
filter out probe sets whose expression levels have both
too little variability and too low intensity among the cell
lines [20,21].
Although it is possible that some of the probes that are
filtered out during this step could potentially measure
activity of a biologically relevant process, the purpose here
is to filter out probes that are not well-measured and keep
probes that are. This step is expected to improve the per-
formance of our techniques without introducing bias into
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Page 7 of 17Figure 3 Out-of-bag error computation schematic. A schematic to illustrate the out-of-bag error computation procedure to determine the
optimal regularization parameter value(s) for the Lasso, RDA, or SNSS, in the context of the dacetuzumab sensitivity classification case study. We
repeat the following B times. We sample the N cell lines in the full cell line data N times, thus creating a bootstrap data set that will serve as our
training sample. The approximately 37% of the cell lines left out of the bootstrap data set as a result of the sampling procedure will serve as an
out-of-bag sample. We perform feature selection and construct a classifier using the bootstrap data, which we use to classify each of the cell
lines in the out-of-bag sample as dacetuzumab sensitive (0), semi-sensitive (1), or resistant (2). For each cell line, we determine its final out-of-
bag sensitivity classification by tallying up the classifications we obtained during the times the cell line appeared in the out-of-bag sample and
selecting the sensitivity according to a majority vote. We compare the final out-of-bag classifications to the true sensitivities to determine the
out-of-bag error.
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based on statistics that are independent of the test statistic;
as is the case here since the probe set intensity and varia-
bility levels are independent of the sample phenotypes;
will result in an increase in power to detect differentially
expressed genes while maintaining proper control of the
rate of detection of spurious genes.
For each probe set, we compute a ratio of the variance
of the expression levels between replicates to the expres-
sion variance between cell lines, and we keep only probe
sets for which this ratio is sufficiently low; the threshold
we use is the first quartile of this ratio among all probe
sets. We then computed the median and mean absolute
deviation of the expression levels of each probe set
among the 31 cell lines; the probe sets we kept con-
sisted of those whose mean expression levels were in
the top quartile among all of the probe sets, or whose
expressions had variances in the top quartile. These pre-
processing steps reduced the number of candidate fea-
tures for selection from 50 thousand to about 4
thousand.
Then we eliminate from the pool of probe sets avail-
able for selection for our classifiers all those not com-
mon to both cell line and patient data; recall that the
cell line genomic data were measured on an Affymetrix
U133Plus2.0 platform and the patient data were mea-
sured on U133A. In this step, we screened out another
1500 probe sets, leaving us with 2500. Finally, we center
and scale both the cell line and patient data such that
the mean and variance of the expressions of each probe
set across samples in each data set are zero and one,
respectively.
T a b l e1a n dF i g u r e4s u m m a r i z et h es u r v i v a lr a t e so f
patients assigned to each dacetuzumab sensitivity class
by each of the nine classifiers. Figure 4 depicts Kaplan-
Meier plots for each sensitivity classification for seven of
the classifiers. Note that we have excluded the Lasso/
Lasso and RDA/RDA classifiers; no genes were selected
for these two classifiers, and they classify all patients as
dacetuzumab resistant. Table 1 lists the genes involved
in each classifier alongside the p-values for log-rank
tests for equality in survival rates between dacetuzumab
sensitive and resistant patients and between patients in
all three sensitivity classes.
A key difference between the classifiers involves the
prognoses of the patients assigned to the semi-sensitive
class. For example, for the SNSS/SNSS classifier, the
survival rates of these patients more closely resemble
those of the resistant classification, whereas for the
Lasso/RF classifier, these survival rates are more similar
to those of the sensitive classification.
Table 2 shows the proportions of GCB, ABC, and
unknown DLBCL subtype malignancies among patients
in each dacetuzumab sensitivity class as assigned by the
seven classifiers where at least one gene was selected.
A very high proportion of predicted dacetuzumab sensi-
tive patients are of the GCB subtype; this proportion is
higher than 80% for the most successful of the classi-
fiers. Also, for the most successful classifiers, a large
proportion of predicted dacetuzumab resistant patients
are of the ABC subtype. For example, 54% of those
patients that the SNSS/SNSS classifier predicted to be
dacetuzumab resistant are of the ABC subtype, whereas
only 20.8% of these patients are of the GCB subtype.
For the Lasso/RF classifier, 47% of the patients classified
as dacetuzumab resistant are of the ABC subtype, and
36% of these patients are of the GCB subtype. Finally,
for most of these classifier, the patients classified as
dacetuzumab semi-sensitive were largely of the GCB
subtype; one notable exception to this is the SNSS/
Table 1 Differences in survival between patients assigned to each dacetuzumab sensitivity class according to each
classifier.
Classifier Selected Genes Sens/Semi/Resis
Log-rank p-values
Sens/Resis Log-rank
p-values
SNSS/SNSS 2 genes total: RGS13, HSP90B1 0.0013 7 × 10
-4
Lasso/RF 10 genes total: RGS13, CRTC3, PRPSAP2, PVRIG,
SORD, WIPF1, CSNK2A2, GNB5, ERAP1, CAMSAP1
0.0125 0.0212
Lasso/KNN 1 gene total: RGS13 0.0304 0.0077
RDA/RF 11 genes total: GRK5, GNB5, IFITM1 (2 probe sets selected), CSNK2A2,
SCARB1, UGDH, MSH2, GORASP1, PECI, VPS54, WWOX
0.0573 0.34
SNSS/KNN 2 genes total: RGS13, HSP90B1 0.0706 0.4661
SNSS/RF 12 genes total: RGS13, HSP90B1, PRPSAP2, IFITM1, SORD, PYROXD1, EVI2B, ZNF322A,
NAGK, BTG2, RAB13, DPYD
0.1513 0.0556
RDA/KNN 2 genes total: GRK5, IFITM1 (2 probe sets selected) 0.4373 0.3035
Lasso/Lasso No genes selected - -
RDA/RDA No genes selected - -
The genes selected by each classifier are summarized alongside p-values for the log-rank tests for differences between the survival rates of dacetuzumab
sensitive, semi-sensitive, and resistant patients, and for the two-way difference between the survival rates of dacetuzumab sensitive and resistant patients only.
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Page 9 of 17Figure 4 Kaplan-Meier plots: survival rates of patients classified as dacetuzumab sensitive, semi-sensitive, and resistant by each of our
classifiers. Blue curves indicate dacetuzumab sensitive patients, green curves semi-sensitive, and red curves resistant. We omit two classifiers that
involved no genes and hence classified all patients with the same dacetuzumab sensitivity.
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Page 10 of 17SNSS classifier, where the subtypes are GCB and ABC
subtype proportions are more even.
Table 2 also provides odds ratios, with 95% confidence
intervals, comparing the odds that a patient classified as
s e n s i t i v eh a saG C Bs u b t y p em a l i g n a n c yt ot h eo d d s
that patient classified as resistant has a GCB subtype
malignancy. For simplicity, the semi-sensitive class is
excluded from this summary statistic. Out of all seven
classifiers listed in Table 2, only one (RDA/KNN) had a
confidence interval that contained one; for the other six,
we have strong evidence for an association between clas-
sification and subtype.
Some of the most commonly recurring genes in these
classifiers include RGS13, HSP90B1, and IFITM1. Regu-
lator of G-protein-mediated signal transduction 13
(RGS13) is a nuclear factor that suppresses CREB-depen-
dent gene expression [23] expressed predominantly in
germinal center B-cells and thymic epithelial cells [24].
These findings would be consistent with the our observa-
tions that RGS13 is expressed at higher levels in the GCB
subtype of NHL cell lines. Furthermore, Heat shock pro-
tein 90 kDa beta, member 1 (HSP90B1) is a member of
the HSP90 family of proteins. Intriguingly, HSP90B1 has
been found to play a role in the regulation of MHCII
a n t i g e np r e s e n t a t i o ni nBc e l l so fe x o g e n o u sa n de n d o -
genous antigens [25] and could explain the increased
expression observed in the ABC subtype of NHL cell
lines. Interferon induced transmembrane protein 1
(IFITM1) is induced by IFN-gamma and functions to
prevent the proliferation of cells infected with virus via
stabilization of the tumor suppressor, p53 [26]. Higher
expression levels of IFITM1 were also found to be asso-
ciated with improved survival of CML patients [27]. The
increased expression in the ABC subtype cell lines we
observed makes biological sense since hyperproliferation
and somatic mutation are events that are no longer
required for a B-cell that will be selected for maturation.
Other commonly recurring genes include G protein-
coupled receptor kinase 5 (GRK5), which is stabilized by
HSP90 [28] and plays a role in activation of the NFkap-
paB signaling pathway by phosphorylating key residues
of IKKbeta [29]; CREB regulated transcription coactiva-
tor 3 (CRTC3), a transcriptional coactivator for CREB as
part of the TORC signaling pathway [30]; and Phos-
phoribosyl pyrophosphate synthetase-associated protein
2 (PRPSAP2), a non-catalytic subunit of the phosphori-
bosylpyrophosphate synthetase enzyme, which is an
essential part of purine, pyrimidine, nucleotide, histidine,
tryptophan and NAD synthesis [31].
T w og e n e s ,L M O 2a n dC D 4 4 ,w e r en o ts e l e c t e di n
any of these models but are components of previously
published GCB/ABC classifiers [32]. Burington et al
( B u r i n g t o n ,B . ,Y u e ,P . ,S h i ,X . ,e ta l :CD40 Pathway
Activation Status Predicts the Anti-Tumor Activity
of CD40 Therapy in Diffuse Large B-Cell Lymphoma,
submitted) hypothesize that dacetuzumab sensitivity in
tumor B-cells is associated with an inactive CD40 path-
way, which in turn is characteristic of normal germinal
center B-cells, while the CD40 pathway in normal acti-
vated B-cells is active. While there is a strong associa-
tion between the two classifiers and a biological
relationship to an important pathway in B-cell matura-
tion, the classifier trained using dacetuzumab sensitivity
m a yb em o r ef o c u s e do nt h eC D 4 0p a t h w a ya n di sa
better predictor of sensitivity.
Second Case Study: ER Status Classification
T h es a m em e t h o d o l o g yi su s ed to construct ER status
classifiers from cell line data. The published patient data
also contain ER status information [10].
We performed pre-processing steps in a manner simi-
lar to the dacetuzumab sensitivity case study. Unlike in
Table 2 Predicted dacetuzumab sensitivity versus GCB/
ABC subtype
Classifier Odds Ratio/95% CI GCB ABC Unknown
Lasso/RF ∞ Sens 0.824 0 0.176
Semi 0.655 0.167 0.179
Resis 0.359 0.427 0.214
SNSS/SNSS 208
(25.40, 1703.23)
Sens 0.889 0.011 0.100
Semi 0.361 0.373 0.265
Resis 0.208 0.542 0.250
SNSS/RF 81.71
(10.50, 635.96)
Sens 0.898 0.020 0.082
Semi 0.625 0.205 0.170
Resis 0.250 0.464 0.286
SNSS/KNN 29.03
(6.53, 129.17)
Sens 0.769 0.031 0.200
Semi 0.591 0.303 0.106
Resis 0.344 0.400 0.256
Lasso/KNN 6.38
(2.69, 15.16)
Sens 0.613 0.132 0.255
Semi 0.600 0.338 0.062
Resis 0.320 0.440 0.240
RDA/RF 4.31
(1.91, 9.72)
Sens 0.657 0.157 0.186
Semi 0.612 0.194 0.194
Resis 0.393 0.405 0.202
RDA/KNN 2.31
(0.95, 5.61)
Sens 0.661 0.161 0.179
Semi 0.477 0.295 0.227
Resis 0.532 0.299 0.169
The odds ratio for GCB subtype by dacetuzumab sensitive versus resistant
classification, with a 95% confidence interval. The GCB/ABC/Unknown subtype
distribution is shown also for the semi-sensitive class, this class is excluded
from the odds ratio calculation for simplicity. Two of the classifiers, Lasso/
Lasso and RDA/RDA, selected no genes and have therefore been excluded
from this table.
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Page 11 of 17the first case study, here, technical replicates of the cell
line data sets were not available, so screening by relative
within-to-between replicate variability was not possible;
here, we only screened out all probe sets whose expres-
sions among the cell lines had both low variability and low
intensity level. We computed the median and mean abso-
lute deviation of the expression levels of each probe set
among the 47 cell lines; the probe sets we kept consisted
of those whose median expression levels were in the top
quintile among all of the probe sets, or whose expressions
had mean absolute deviations in the top quintile. These
pre-processing steps reduced the number of candidate fea-
tures for selection from 22 thousand to about 7 thousand.
Here, screening out probe sets not common to the cell
line and patient data was not necessary; both the patient
data and cell line data were measured on U133A plat-
forms. Finally, we centered and scaled the probe set
expressions in both the cell line and patient data. A similar
approach was used in Chin et al [10].
Again, we have constructed nine ER status classifiers
using the different combinations of feature selection and
classification techniques, and we assess each of them by
comparing the classifications with known phenotypes in
the independent patient data. Table 3 summarizes the
performance of the ER status classifiers. The misclassifi-
cation rate here is defined as the proportion of patients
whose classifications do not match their known pheno-
types. For the most successful classifiers, this misclassifi-
cation rate is approximately 10%. The classifiers with
the lowest misclassification rates involve only one or
two genes, and these classifiers all involve ESR1, which
encodes estrogen receptor.
Discussion
In each of the case studies, we were able to construct at
least a few low-dimensional classifiers that generalized
well from cell line data to patient data using some
combination of feature selection and classification
techniques.
The patient ER status assignments from some of the
classifiers, particularly SNSS/SNSS and Lasso/RF, had
low misclassification rates. For the most successful ER
status classifiers, this misclassification rate was about
10% to 12% and only one or two genes were required.
Meanwhile, some of the dacetuzumab sensitivity classi-
fiers, notably SNSS/SNSS and Lasso/RF, had good prog-
nostic ability. For these classifiers, dacetuzumab
sensitivity classifications seemed to overlap with the
prognostic GCB versus ABC DLBCL subtype; patients
classified as dacetuzumab sensitive were largely of the
GCB subtype whereas those classified as dacetuzumab
resistant were largely of the ABC subtype, and this is
evident in both the difference in survival rates between
the dacetuzumab sensitive and resistant classes (Figure 4
and Table 1) as well as the strong association between
GCB versus ABC subtype and dacetuzumab sensitivity
and resistance (Table 2). Because of the coincidence of
the prognostic and predictive pathways in this particular
case, these classifiers are hypothesized to have good pre-
dictive ability as well. This hypothesis is currently being
tested in a randomized Phase II trial in second line
DLBCL.
Note that we assess the performance of our classifiers
primarily in terms of the sensitive and resistant classes.
Even for the most successful classifiers in this case
study, prognoses for patients classified as dacetuzumab
semi-sensitive still remained somewhat mixed. Semi-
sensitive cell lines were somewhere in between sensitiv-
ity and resistance, sharing expression patterns with both
types, and this makes them difficult to identify correctly.
During the out-of-bag error computations steps in the
construction of each classifier, we rarely classified dace-
tuzumab sensitive cell lines as resistant or vice versa;
two notable outlying exceptions to this were the cell
Table 3 Performances of ER status classifiers
Classifier Selected Genes Patient Prediction Error
SNSS/SNSS 1 gene total: ESR1 0.1017
Lasso/KNN 1 gene total: ESR1 0.1186
Lasso/RF 1 gene total: ESR1 0.1186
SNSS/RF 2 genes total: ESR1, TOM1L1 0.1186
SNSS/KNN 2 genes total: ESR1, TOM1L1 0.161
Lasso/Lasso 19 genes total: ESR1, TOM1L1, CPT1A, SRPR, APOD, COIL, CYB561,
C10orf116, ST6GALNAC2, MICALL1, ABAT, FBP1, CA12, JAG1, PDCD4,
FXYD5, RSAD1, C14orf132, MRPL35
0.1864
RDA/RDA 7 genes total: ESR1, EIF3D, CPT1A, COIL, INPP4B, SIAH2, RSAD1 0.4661
RDA/RF No genes selected 0.5254
RDA/KNN 1 gene total: CPT1A 0.5254
Summaries of the performances of the nine ER status classifiers, including the selected genes and the patient ER status prediction error.
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Page 12 of 17lines SU.DHL.8 and Karpase.422. We did observe some
sensitive and resistant cell lines being misclassified as
semi-sensitive and semi-sensitive cell lines frequently
being classified as sensitive or resistant. Most of the
out-of-bag classification errors were a result of these
semi-sensitive cell lines.
This is also reflected in the patient data. The survival
rates of patients classified as dacetuzumab semi-sensitive
sometimes resembled the survival rates of those classi-
fied as sensitive, as what happened with the Lasso/KNN
classifier. In other cases, such as the SNSS/SNSS classi-
fier, the survival rates of patients classified as semi-
sensitive more closely resembled those of the resistant
class. The distribution of GCB versus ABC subtypes
among patients classified as semi-sensitive also is some-
what ambiguous; for some classifiers, such as Lasso/RF,
Lasso/KNN, and SNSS/RF, the semi-sensitive patients
are predominantly of the GCB subtype, whereas for
others, such as the SNSS/SNSS classifier, a much larger
proportion of the semi-sensitive patients are of the ABC
subtype.
Because of the ambiguous nature of semi-sensitive
samples, combining them with either resistant or sensi-
tive samples is not likely to be helpful. Nevertheless, in
terms of constructing the classifiers themselves, they
were helpful as a separate ordered category since many
outcomes trended on average from sensitive through
semi-sensitive to resistant. During gene selection, some
genes exhibited trending intensity through the semi-sen-
sitive cell lines and excluding these cell lines did not
improve the performance of gene selection or classifica-
tion in this application (excluding intermediate samples
is a technique worth trying). Also, the semi-sensitive
class may provide insight into the relative positive versus
negative predictive value of competing classifiers and
therefore whether they would be more useful for maxi-
mizing the response rate or excluding non-responders
in clinical practice. Classif i e r ss u c ha sS N S S / S N S S ,
where the prognoses of patients classified as semi-sensi-
tive more closely resemble those of patients classified as
resistant, have high positive predictive value and are
best for maximizing the response rate. Meanwhile, clas-
sifiers such as Lasso/RF and SNSS/RF, where the prog-
noses of patients classified as semi-sensitive more
closely resembles those of patients classified as sensitive,
have high negative predictive value may be best suited
to settings that require high confidence in predictions of
non-response.
Here, we introduce SNSS, a novel forward stepwise
procedure that is designed to model either up/down
regulated pathways or pathways better represented by
independent probe selection. The two case studies illus-
trate each approach. The former approach is more
appropriate when unsupervised clustering suggests the
presence of multi-gene up-to-down regulated contrasts,
for example appearing as a red versus green four-square
in a heat map. It modifies the stepwise procedure to add
anti-correlated pairs rather than choosing the single
strongest predictor. The latter approach is essentially
forward stepwise, which is more appropriate for situa-
tions where one or more pathways are distinctly charac-
terized by dysregulation of one or a few genes (e.g.
FGFR3 and MMSET in t(4;14) multiple myeloma [33]).
Future work will extend the model to include both types
of pathways in a single model and generalize the for-
ward stepwise approach to the addition of small clusters
of positively and negatively correlated genes.
In these case studies, SNSS performed well in both
feature selection and model fitting. In particular, SNSS
with SNSS, as well as Lasso with Random Forests, pro-
duced classifiers that were successful in both generaliz-
ing from the cell line to the patient data and requiring
only a small number of genes. These results, however,
are not sufficient to suggest that these two combinations
are inherently the best feature selection and classifica-
tion techniques for deriving classifiers from cell line
data. This simply suggests that these two combinations
were the best for these particular case studies. The char-
acteristics of these data sets may have just been condu-
cive to the success of these two combinations. In data
involving more cell lines, for example, the SNSS/SNSS
and Lasso/RF classifiers may be outperformed by others.
Answering the question of when a particular classifier
will or will not perform well requires further research.
SNSS may perform better as a feature selection techni-
que when the size of the training data is small, the data
contain a large number of correlated variables, and the
platform on which the patient assay is implemented dif-
fers from the cell line platform used for assay develop-
ment (i. e. non-identical distributions of the gene
expression measurements). Under these circumstances,
the hard-thresholding of SNSS based on simple signed
averages may match or outperform more complex fitting
procedures such as Lasso. On the other hand, if the
patient and cell line genomic data are measured on
identical platforms and the size of the training set were
larger, more complex fitting techniques may improve
the classification accuracy; in these conditions, SNSS-
based classifiers may not perform as well.
However, RDA may not be the best feature selection
method for the purposes of constructing PCR-based
assays. Both the Lasso and SNSS are inherently effective
at keeping the number of genes involved small. The
Lasso can only select at most N genes, where again, N is
the number of cell lines, and since in these types of situa-
tions, N is usually small, the number of genes involved in
a Lasso-based classifier is also generally small. In SNSS,
we directly control the number of genes involved. Guo
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and often does, select more than N genes [16].
Although we use linear models for feature selection
and classification, none of our reported estimates of
accuracy depend upon whether or not a linear model
holds strictly. Approximatel o g n o r m a l i t yi sw e l ls u p -
ported by descriptive analyses of these data (not shown
for reasons of space) as well as being common in the lit-
erature. It is well known that the signal properties of
microarrays are skewed and that using the log signal
improves the signal properties by reducing heteroskeda-
city [34]. The linear methods that we used for the most
part performed reasonably well with roughly approxi-
mately normal data. It is important, however, that our
assessment of their performance does not rely on the
model assumptions, because violations can impact
model performance. For example, for RDA spherical dis-
tributions of the data within class and for the Lasso nor-
mality of the errors improve the modelfit. In addition,
marked violations of assumptions required for valid
inference, such as homoskedasticity, may lessen the
optimality of feature selection procedures that use linear
models. We believe that these are all good reasons to
compare approaches in applied settings, as we do in this
manuscript.
Conclusions
Our primary aim was to develop predictive or prognostic
assays from cell line genomic data that not only general-
ize well to patient data but are also feasible to implement
in practice; in other words, we wanted to develop assays
that not only assign phenotypes to patients given their
genomic data with high accuracy, but also involve a small
number of genes. To this end, we applied feature selec-
tion techniques in conjunction with classification meth-
ods to cell line data to (1) find a small subset of the most
important genes, and then (2) develop an appropriate
classification rule given the expression levels of these
genes. We assessed these classifiers by applying them to
independent patient genomic data.
For each of our case studies, we constructed nine dif-
ferent classifiers using different combinations of feature
selection and classification techniques. Not all of the
feature selection and classification method combinations
we considered produced classifiers that both generalized
to patient data well and involved a small number of
g e n e s ,b u ti ne a c hc a s es t u d y ,w ew e r ea b l et op r o d u c e
at least a few classifiers that were successful in this
regard. In particular, SNSS with SNSS and Lasso with
Random Forests produced low-dimensional classifiers
that assigned patient phenotypes with high accuracy in
each of the cases studied here.
These results demonstrate the feasibility of combining
feature selection techniques such as the Lasso, SNSS,
and RDA with classification methods such as KNN and
Random Forests in order to develop assay based on
genomic measurements from cell lines that subsequently
exhibit good performance in patients. Even though two
particular feature selection and classification method
combinations performed well in these case studies, in
other settings, different combinations may outperform
them. The question of what general conditions deter-
mine the relative performance of the combinations
remains open.
Appendix
The Lasso
Denote Yi as the value of Y and Xij the value of Xj for
sample i. The Lasso estimates of the bj are the bj that
minimize
YX ii j
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for some shrinkage parameter l ≥ 0. The first term of
(3) encourages ˆ  j values that provide a good fit to the
data and the second term performs feature selection and
regularizes the minimization problem.
Without the second term, the minimization problem
is ordinary least squares [5], which is degenerate when
p ≫ N as is the case in these two case studies, since the
data can then be interpolated. Also, the solution to the
ordinary least squares minimization problem has ˆ  j =0
with zero probability, so this minimization does not per-
form feature selection.
T h eg e o m e t r yo ft h eL1-norm penalty, the second
term in (3) sets ˆ  jequal to exactly zero for many j, thus
performing feature selection simultaneously with fitting.
The number of nonzero ˆ  jis controlled directly through
l; small values of l result in low weight to the L1-norm
penalty and therefore many nonzero ˆ  jestimates, or
many variables being selected, and as l increases, so
does the weight of the penalty. The number of selected
variables consequently decreases.
The Lasso will select at most N variables [4].
RDA
RDA is a variant of Linear Discriminant Analysis (LDA)
[17] which is particularly useful for cases where N ≫ p.
Again, we define sub-populations based on the pheno-
types; for each sub-population, the gene expressions
have their own multivariate Normal distribution.
We assume the variances Σ do not differ between sub-
populations, but the mean gene expressions μk do. LDA
is unstable for when N ≫ p since ˆ Σ , the maximum
likelihood estimate of the variance will not be full rank
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 ΣΣ =+ −  ˆ () 1 Ip (4)
in place of ˆ Σ ,w h e r e0≤ a <1a n dIp is the p × p
identity matrix.
Additionally, in RDA we may shrink each element of
 Σ
−12 / ^ iby some Δ > 0, which will perform gene selec-
tion [16]. More specifically, let zi be the i
th element of
 Σ
−12 / ^ i;t h e nw er e p l a c e  Σ
−12 / ^ i with a vector whose
i
th element is given by
zz z ii i
∗
+ = () − () sgn Δ (5)
SNSS
As mentioned before, at each step of SNSS, we have the
option of adding to the predictive model a single gene
with predictive signal or a pair of genes: a gene with
predictive signal and its most negatively correlated gene.
In either case, the main gene is selected according to
the strength of its correlation with the residuals; if we
choose to select pairs of genes at each step, the other is
the gene whose expression is most negatively correlated
with that of the main gene. Also, unlike Lasso and RDA,
the values of ˆ  j we obtain from SNSS are restricted to
{-1, 0, 1}.
Define mk as the index of the main gene of the k
th
pair and pk as the index of the corresponding pair gene.
Define the residual of sample i, Ri,a s
RY X X ii m i m p i p
k
kk k k =− + ⎡
⎣
⎤
⎦ ∑
ˆˆ  (6)
If no gene pairs have been selected, Ri = Yi. Also, if we
only opt to select single genes at each step, bpk always
equals zero.
For the SNSS procedure, we need to specify K,t h e
total number of steps to take. If we opt to select pairs of
genes at each step, K i st h en u m b e ro fg e n ep a i r st o
include in the predictive model; otherwise, K is the
number of genes to include. Then
Ri ¬ Yi for each i = 1, 2, ..., N
for k = 1, 2, ..., K do
main gene ¬ gene whose expression has strongest
correlation with Ri, i. e., find mk = argmaxj |Corr [Ri, Xj ]|
ˆ mk ¬ sgn(Corr[Ri, Xj])
if we are selecting pairs of genes then
pair gene ¬ gene whose expression is most nega-
tively correlated with main gene, i. e., find
pX X kj m j k = argmin , Corr[ ]
ˆˆ  pm kk ←−
end if
if we are selecting pairs of genes then
RR X X iim i mp i p kk k k ←− + ⎡
⎣
⎤
⎦
ˆˆ 
else
RR X ii m i m kk ←− ˆ 
end if
end for
KNN
Suppose that through the Lasso, RDA, or SNSS, we
have selected the genes X1, X2,. . . ,Xd. Here, we first
identify the single cell line whose expressions for these
d genes are closest to the patient’sa n dt h e na s s i g nt h e
patient’s class according to the known phenotype of this
cell line. In general, the patient classification can be
determined using a majority vote among the k cell lines
whose gene expressions are closest, but because of the
small number of cell lines, we only use the single near-
est cell line here. More specifically, for each cell line,
we compute
DXX X XX X dd ( ( ,, ,) , (,, ,) ) 12 12 ……
∗∗ ∗ (7)
where ( XX X p 12
∗∗ ∗ … ,, ,)a r et h ep a t i e n t ’s expression of
these d genes and D is a distance metric; in our case,
we use Euclidean distance
DXX X XX X X X X X X dd d ( ( ,, ,) , (,, ,) ) ( )( ) ( 12 12 1 1
2
22
2 …… = − + − + … +
∗∗ ∗ ∗ ∗ ∗ − − Xd)
2 (8)
We then rank-order the distances and classify the
patient according to the phenotype of the nearest-
ranked cell line.
Random Forests
Random Forests [6] is an ensemble classifier that con-
sists of many decision trees and outputs the class which
is the mode of the class outputs by the individual trees.
Random Forests uses a random subset of features
selected at each tree node, thus introducing additional
sources of perturbation into the data compared to other
re-sampling techniques such as bagging [18].
We repeat the following B times. We sample from the
N cell lines N times with replacement to create a boot-
strap data set. We then randomly select m out of the d
genes selected through the Lasso, SNSS, or RDA and
construct a classification tree using the expressions of
these m genes based on the bootstrap data. Repeating
this process B times will produce an ensemble of B
trees T1, ..., Tb.
Given a patient’s expressions of the d selected genes,
XX X p 12
∗∗ ∗ … ,, ,, we obtain B classifications through the
ensemble of trees, one for each tree:
Huang et al. BMC Cancer 2010, 10:586
http://www.biomedcentral.com/1471-2407/10/586
Page 15 of 17CT X X X
CT X X X
CT X X X
d
d
BB
11 1 2
22 1 2
12
=…
=…
=…
∗∗ ∗
∗∗ ∗
∗∗
()
()
(
,, ,
,, ,
,, ,

d d
∗)
(9)
The final classification of this patient is determined by
a majority vote among C1, C2, ..., CB.
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